Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Recent advances in the use of targeted therapies for metastatic urothelial carcinoma

Yohann Loriot • 21 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Pembrolizumab Sacituzumab govitecan

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and University of Paris-Saclay, Gif-sur-Yvette, France, discusses up and coming targeted agents in the field of metastatic urothelial carcinoma (mUC), including for FGFR, NECTIN4, TRP-2 and HER2. Promising data demonstrated an overall response rate (ORR) of 30% with sacituzumab govitecan, a Trop-2 targeting agent, in a Phase II trial and trastuzumab plus pembrolizumab has also demonstrated some promising activity. The antibody drug conjugate (ADC), ARC48, targeting HER2 has also shown activity in the metastatic setting of bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Yohann Loriot

Future endeavours with ADCs in bladder cancer
1:05
Future endeavours with ADCs in bladder cancer
Yohann Loriot • 5 Jun 2023
ADCs in the management of urothelial carcinoma
0:58
ADCs in the management of urothelial carcinoma
Yohann Loriot • 5 Jun 2023
Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
0:49
Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
Yohann Loriot • 5 Jun 2023
Safety analysis of TROPHY-U-01 based on UGT1A1 status in mUC
1:22
Safety analysis of TROPHY-U-01 based on UGT1A1 status in mUC
Yohann Loriot • 5 Jun 2023

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals